Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma is supported by telitacicept’s increasingly validated efficacy and safety profile, highlighted by the May 14, 2026 NEJM publication showing a 55.0% placebo-adjusted UPCR reduction at week 39, near-flat eGFR versus decline on placebo, and fewer serious adverse events. The asset’s franchise potential is strengthened by multiple late-stage China wins in SLE, RA, and gMG, plus pending IgAN and SjD regulatory decisions, while Vor retains exclusive rights outside China and is advancing two global Phase 3 UPSTREAM programs. With an estimated ~380K U.S. gMG/SjD patients and potential expansion to >1M, the company has a large addressable market and meaningful optionality from a clinically derisked, first- and best-in-class dual BAFF/APRIL inhibitor.

Vor Biopharma is facing a highly uncertain fundamental profile because its valuation depends heavily on telitacicept, a single lead program whose projected value is tied to risk-adjusted future revenues rather than proven, durable commercial execution. The key downside is that clinical and regulatory failure in target indications, safety issues, or weak efficacy could halt development, while competition from current and future therapies may prevent the company from reaching sales estimates even if approval is achieved. With risks also spanning commercialization, collaboration, dilution, legal, intellectual property, and manufacturing or shipment disruptions, the business remains exposed to multiple failure points despite net cash and cash equivalents of $491.5M.